Background
Dravet syndrome (DS) is a rare developmental and epileptic encephalopathy [
1,
2]. Patients experience refractory epilepsy and numerous non-epileptic manifestations, such as impaired cognition, speech impairments, and delayed motor and behavioral development [
3,
4]. The incidence of DS is estimated to be 1 in 15,000 live births, with a prevalence of 2 in 100,000 people [
5‐
7]. In most patients, DS is caused by a mutation in the sodium channel protein type 1 subunit alpha (
SCN1A) gene, which encodes a voltage-dependent sodium channel (Nav1.1) [
8,
9].
Frequent, prolonged seizures develop during the first year of life in otherwise normal infants and are typically triggered by fever. Mortality in DS is high due to an increased risk of sudden unexpected death in epilepsy and frequent episodes of status epilepticus (SE) [
10,
11].
The major focus of research in DS has been on the development and treatment of refractory epilepsy and associated clinical and pathophysiological issues. Recently, studies have begun to address the impacts of DS on caregivers and the family environment [
12‐
14]. An international survey of 256 parents and caregivers identified impacts on siblings (74%) and possible depression in caregivers (66%) as major issues associated with caring for patients with DS, requiring more extensive research [
15]. Another survey of 34 primary caregivers highlighted anxiety; depression; impacts on physical and emotional wellbeing; and time constraints as major problems encountered in caring for patients with DS [
16]. Jensen et al. identified sleep deprivation, reduced mental health, deterioration of social relationships, and financial burden as major concerns among caregivers [
17]; they authored a paper highlighting some of the open research questions in the field of DS, including the psychosocial impacts of caring for patients with DS [
18]. A recent study by Nabbout et al. analyzed survey responses from 87 caregivers of patients with DS in France, highlighting the broad social and economic impacts on caregivers, especially mothers [
19]. Although caregivers have reported sleep disturbances as critical factors impacting the quality of life of patients with DS who experience frequent seizure-related and non-seizure-related-awakenings, no comparable studies have examined the impacts of sleep disturbances on the quality of life of caregivers[
20] or the various methods parents use to monitor their children’s sleep [
21].
To address some of these identified open research questions, we conducted a study focusing on sleep quality among caregivers of DS patients. To the best of our knowledge, this study represents the first attempt to quantify sleep issues among caregivers of patients with DS using the well-established Pittsburgh Sleep Quality Index (PSQI), which will allow us to contextualize and evaluate the severity of previously identified sleep and mental health issues experienced by caregivers.
Material & methods
This multicenter, cross-sectional study enrolled primary caregivers of patients with DS throughout Germany (via specialists in Berlin, Bielefeld, Dresden, Erlangen, Frankfurt, Freiburg, Giessen, Heidelberg, Hirschaid, Kiel, Kork, Leipzig, Lingen, Münster, Rostock, Tübingen, Vogtareuth and through the German DS patient advocacy group [Dravet Syndrom e.V., Markkleeberg, Germany]). Written informed consent was obtained from the parents or legal guardians of patients with DS. The study obtained ethics approval from Goethe-University Frankfurt, Frankfurt am Main, and was registered with the German Clinical Trials Register (DRKS00016967). The Strengthening and Reporting of Observational Studies in Epidemiology (STROBE) guidelines were closely followed during the conduct and reporting of this study [
22].
A combined survey, consisting of a previously validated retrospective questionnaire and a prospective diary [
23], was administered to enrolled participants in Germany in 2019. Both the questionnaire and diary were linked to an anonymous identification number. The questionnaire consisted of 57 questions relating to disease characteristics (seizures, medical treatment, comorbidities, care level, disability degree), demographic data, the living conditions of both patients and caregivers, the work situation of caregivers, and nocturnal supervision details (monitoring and use of devices). This data was supplemented with information on the presence or absence of a disability (Grad der Behinderung) and the child’s care level (Pflegegrad), both provided by the caregiver but having been independently assessed by the social security office (Versorgungsamt) and the nursing care insurance system (Pflegeversicherung) that includes a mandatory medical assessment by a physician [
13]. The questionnaire included both closed and open-ended questions; closed questions included responses that were list-based, multiple-choice options, or Likert scales.
In addition, the PSQI, Hospital Anxiety and Depression Scale (HADS), and Burden Scale for Family Caregivers (BSFC) were included in the questionnaire. The PSQI is a widely used, well-validated measure of sleep that consists of seven subcategories: sleep quality, duration, latency, efficiency, disturbances, daytime dysfunction, and use of sleep medication. Scores (range: 0–21) above 5 are considered to indicate a sleep problem [
24,
25].
The HADS, a validated and well-known tool for measuring anxiety and depression consisting of 14 items, was used to assess mental health. Higher scores on the subscales for anxiety (HADS-A, range: 0–21) and depression (HADS-D, range: 0–21) indicate higher levels of stress. In this study, we used cutoff values of 8 for both subscales to indicate possibly abnormal levels of depression and anxiety. Values of 11 or above were considered indicative of a high likelihood of depression or anxiety. According to various studies in the literature, a cutoff value of 8 represents the optimal balance between sensitivity and specificity for the HADS [
26,
27].
The BSFC is a 28-item instrument used to quantify the perceived burden of family caregivers. The total score (range: 0–84) indicates three levels of burden: a total score ≤ 41 correlates with no to mild stress with no increased risk of developing psychosomatic symptoms; a score of 42–55 indicates moderate stress, associated with an increased risk of developing psychosomatic symptoms; and a score ≥ 56 indicates severe to very severe stress, associated with a very high risk of developing psychosomatic symptoms [
28,
29]. The questionnaire had to be filled by the main caregiver who is defined as a the person spending the most time with caring for the patient with Dravet syndrome. The main caregiver had to complete the questionnaire, answering questions about a retrospective time period of three months. The estimated time for completion was about one hour.
The prospective diary collected data on seizures, monitoring, and emergency treatment for one month and was used to validate diurnal and nocturnal seizure frequency data reported in the retrospective questionnaire.
Statistical analysis was conducted using IBM SPSS version 27 (IBM Corp., Armonk, NY, USA). Variables of interest were summarized using the mean, median, range, and standard deviation (SD). Pearson’s correlation coefficient was calculated for continuous variables. Correlations with coefficients < 0.3 were not considered for interpretation based on Cohen’s definitions (< 0.3 is a low correlation; 0.3–0.5 is a medium correlation; > 0.5 is a high correlation) [
30]. The Wilcoxon signed-rank test was performed to compare factors influencing sleep quality, anxiety, depression, and caregiver burden. A two-sided significance level of
p = 0.05 was used in all statistical analyses. A Chi-square analysis was performed to compare our cohort with the normal population.
Discussion
The majority of primary caregivers for patients with DS reported low sleep quality, which correlated with anxiety and depression symptoms and a high caregiver burden. Our findings support the notion that DS is a multifactorial disease presenting not only with refractory epilepsy but also with numerous symptoms and comorbidities that affect caregivers and the family environment [
3]. Supportive therapy and services should be offered to a substantial proportion of caregivers to help them in their daily lives.
Our findings are in line with other studies reporting significant impacts experienced by the caregivers of patients with DS. Almost half of the caregivers (45.3%) in our cohort perceived at least a moderate burden as measured by the BSFC. In addition to high seizure and SE frequencies, numerous comorbidities affect behavior, motor skills, development, vegetative dysfunction, cognition, communication, and sleep in patients, which impact the quality of life for both patients and their caregivers [
4,
15,
19,
32‐
34].
The totality of these impairments results in an overall disability level that affects the sleep quality of caregivers. As observed in our results, caregivers’ sleep quality is highly dependent on their anxiety level (r = 0.456; p < 0.001) and the overall impact of comorbidities (r = 0.367; p < 0.001), particularly sleep disturbances among patients with DS. Contrary to expectations, nocturnal seizures and monitoring had no significant impacts on the PSQI. However, a higher frequency of seizures resulted in a higher caregiver burden and a higher anxiety level.
Sleep disturbances among patients with DS have previously been addressed in the literature. Losito et al. retrospectively analyzed clinical and electroencephalogram data of patients with DS to detect sleep-related and nocturnal seizure clusters. They stated that the sleep quality for both the patient and their caregiver might be worsened by certain sleep patterns and nocturnal seizures occurring between the ages of 4 and 11 years, which are often underdiagnosed [
35]. Licheni et al. demonstrated that sleep disturbances represent an important problem among patients with DS patients based on the outcomes of the Sleep Disturbance Scale for Children and a seizure questionnaire, although the incidence of sleep disturbances reported in their cohort was higher (75%) than that in ours (63.9%). Furthermore, they reported that most difficulties were associated with initiating and maintaining sleep, particularly among patients older than 20 years. Our study confirmed that sleep disturbances among patients with DS were an important risk factor for sleep deprivation and poor sleep quality among caregivers and elaborated on their impacts on anxiety levels and the perception of caregiver burden.
To our knowledge, this is the first study to use the PSQI to quantify sleep problems among caregivers of patients with DS. The PSQI is recommended in the current guidelines of the German Society for Sleep Medicine and Sleep Research[
36] and has been shown to be reliable [
37]. The proportion of poor sleepers in our cohort (76.9%) was double the proportion among the general German population [
31]. Lower sleep quality in caregivers of patients with DS was positively correlated with anxiety symptoms and perceived caregiver burden; a minor, positive correlation was also observed with depressive symptoms. Moreover, Pearson’s coefficients indicated the highest correlations between sleep quality and anxiety level.
A study performed in Spain examined PSQI values among informal caregivers of individuals whose degree of dependence ranged from moderate to total due to various physical disabilities and mental disorders [
38]. The study divided 201 caregivers into two groups according to their perceived burden (measured by the Caregiver Burden Inventory) and reported mean PSQI scores of 7.0 and 10.4 for those with low and high perceived burdens, respectively, whereas a control group had a mean PSQI score of 5.9. The PSQI values of caregivers for dependent individuals in Spain were similar to the results observed in our study. A high rate of sleep difficulties in young children with epilepsy and their parents was reported by Reilly et al. [
39]; 62% of mothers and 44% of fathers reported poor sleep quality on the PSQI. However, the authors did not observe a significant difference between mothers of children with epilepsy and in a non-epilepsy-related neurodisability group [
39]. There is a need to develop effective interventions for this population, taking into consideration of the role of child behavioral problems and parental mental health difficulties. A recent publication evaluated anxiety, depression, and sleep quality among parents of children with epilepsy in Southern China [
40]. They reported a mean PSQI score of 6.9, which was significantly higher than the mean of 5.0 scored by the parents of healthy children. Another study examining caregivers of physically disabled children in Japan reported a mean total PSQI score of 4.9, with 34% of caregivers rated as poor sleepers [
41]. Chu and Richdale examined the caregivers of children with developmental disabilities and found a mean PSQI score of 8.8 [
42]. Our findings indicate that sleep quality is highly affected among caregivers of patients with DS, and compared with the caregivers of physically disabled children and of children with epilepsy, in general, the proportion of poor sleepers was larger among caregivers of patients with DS.
Villas et al. designed an online survey for the parents and caregivers of patients with DS to identify the top concerns among caregivers and establish approximate frequencies of characteristics and comorbidities associated with DS beyond seizures. They stated that an alarmingly high percentage of caregivers (80%) slept in the same bed as patients with DS for safety reasons, which could lead to significant sleep disturbances experienced by both the caregiver and the patient. Another parent-driven online survey, conducted by Van Nuland et al., queried patients' sleep disturbances and showed that 59% of parents used co-sleeping as a monitoring method. Although fewer caregivers in our cohort (33.3%) slept in the same bedroom or even the same bed as the patient (22.6%), a significant impact on depression and anxiety symptoms was observed among these individuals; however, these impacts were not directly apparent on the PSQI. Our cohort was similar to the cohort studied by Villas et al. (92%
SCN1A mutations, median age 7–10 years, patients’ recruitment by means of an advocacy group) [
9]; however, the surveys were conducted several years apart, and modern supervision devices might have replaced co-sleeping among our cohort.
Sleep quality should receive more attention in daily treatment, as the sleep quality among caregivers of patients with DS appears to be deeply affected, exceeding the effects reported for caregivers of patients with other rare diseases [
43]. One possible approach is to examine the effects of brief behavioral sleep interventions. For example, one study examined interventions that included stimulus control, relaxation, cognitive therapy, and sleep hygiene elements, measuring self-reported sleep quality, depressive symptoms, and quality of life among 30 caregivers of patients with cancer, which showed that participants who received interventions improved PSQI scores compared with a control group [
44]. Behavioral interventions have also been shown to be effective in primary insomnia [
37]. The first intervention for improving sleeping problems is to inform caregivers about sleep hygiene tools that can easily be implemented in daily treatment routines. In addition, patients' sleep problems and the shared sleep situation between patients and caregivers should be taken into consideration. A more detailed analysis of nocturnal monitoring devices could provide a new study base for the presentation of alternatives to co-sleeping. Furthermore the introduction of new ASMs like cannabidiol and fenfluramine might have an effect on patients’ sleep quality [
45‐
47], but this needs to be evaluated in future studies. Another approach to addressing sleep problems would be to target caregivers’ anxiety levels as the primary factor influencing PSQI scores.
The limitations of this study include the study design, as surveys are susceptible to response and recall biases. To limit recall biases, data from the questionnaire were validated using the prospective diary. Individual clinical examinations would have provided further insights into the precise contributions of depression or anxiety to quality of life, but these were beyond the scope of this questionnaire-based study. We have to emphasize that no clinical diagnosis of depression is made in caregivers based on our survey data. Therefore, only symptoms of depression and anxiety are discussed. Furthermore, the questionnaire was completed only by the main caregiver. We have considered interviewing both parents and even the siblings; however, the estimated time to answer the questionnaire was about one hour and interviewing both parents and even the siblings would exceed a reasonable amount of time spent on the study from the caregiver’s perspective. Potential selection bias must be considered due to differences in the willingness to participate in studies across different population strata. Moreover, regional or national particularities may have influenced the results; however, the use of established questionnaires and compliance with the STROBE criteria were applied to minimize these aspects to the extent that was reasonably possible [
22].
Some categories, such as degree of developmental delay, were not defined and relied on caregivers' subjective assessments, which may not be representative of a physician's assessment. Furthermore, although the sample consisted of individuals recruited from a variety of sources (multiple clinics and centers across Germany and through the patient advocacy group), the sample may not have been representative of DS patients and their caregivers in Germany in general. One strength of this study was its sample size of 108 patients and caregivers, given the rarity of DS. However, to identify more predictors for sleep quality and mental status, larger sample sizes are needed.
Declarations
Competing interests
MM reports grants from GW Pharmaceuticals. SSB reports personal fees from Eisai, Desitin Pharma, GW Pharmaceuticals, Zogenix, UCB Pharma, and Marinus Pharma. TB has received support from Bial, Desitin Arzneimittel, Eisai, GW Pharmaceuticals, Neuraxpharm, Nutricia, Shire, Takeda, UCB Pharma, and Zogenix. RT reports personal fees from Desitin Pharma, Eisai, and Novartis. MW reports personal fees from Zogenix, Desitin, and Praxis Precision Medicines. KAK reports personal fees from Eisai, GW Pharmaceuticals, Zogenix, and Neuraxpharm. JJ reports personal fees from Eisai, Pendopharm, UCB Pharma, and Epilog. Her research is supported by NSERC and the Alberta Children’s Hospital Foundation. GKu reports honoraria for speaking engagements from Desitin Arzneimittel, Eisai, UCB Pharma, Takeda, Shire, Zogenix, Neuraxpharm, Stada, and GW Pharmaceuticals. SS reports personal fees from Zogenix and fees from Eisai, UCB Pharma, and Nutricia paid to his department. AB reports grants from UCB Pharma and honoraria for speaking engagements from Biogen, Desitin Arzneimittel, Eisai GmbH, GW Pharmaceuticals, Neuraxpharm, Shire/Takeda GmbH, UCB Pharma, and ViroPharma. FR reports personal fees from Angelini Pharma/Arvelle Therapeutics, Eisai, GW Pharmaceuticals/Jazz Pharma, and UCB Pharma and grants from the Detlev-Wrobel-Fonds for Epilepsy Research, the Deutsche Forschungsgemeinschaft (DFG), the Federal Ministry of Education and Research (BMBF), the LOEWE Programme of the State of Hesse, and the European Union. LK reports personal fees from GW Pharmaceuticals. AS reports personal fees and grants from Angelini Pharma, Desitin Arzneimittel, Eisai, GW/Jazz Pharmaceuticals, Marinus Pharma, Precisis, Takeda, UCB Pharma, UNEEG Medical, and Zogenix. The other authors declare that they have no competing interests.
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.